DexCom Announces Upcoming Conference Presentations

Raymond James Institutional Investors Conference 2015
Barclay’s Global Healthcare Conference 2015

SAN DIEGO--()--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:

  • Steve Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Raymond James 36th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 3, 2015 at 9:15am (EST). The presentation, which will occur live at the JW Marriott Grande Lakes, will be concurrently webcast.
  • Steve Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 10, 2015 at 9:30am (EDT). The presentation, which will occur live at the Loews Miami Hotel, will be concurrently webcast.

The link to each webcast will be available on the DexCom website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and finally “Events and Webcasts” and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward-Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on November 6, 2014.

Contacts

DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
858-200-0200

Release Summary

DexCom Announces Upcoming Conference Presentations

Contacts

DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
858-200-0200